Kazia Therapeutics Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KZIA | BBOT | CRDF | OLMA | BDTX | ACRV | |
|---|---|---|---|---|---|---|
| Market cap | 92.33M | 184.40M | 67.60M | 659.73M | 108.87M | 74.56M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1,473.8 | -0.8 | -1.6 | -2.9 | -1.7 | -1.1 |
| Price/book | 2.8 | 0.6 | 2.2 | 1.5 | 1.1 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +7.73% | −81.22% | −61.33% | −7.55% | −53.23% | −13.00% |
| Today | 0.00% | −0.86% | +0.67% | +2.59% | +4.97% | +4.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KZIA news ›Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
The research further explores paxalisib’s differentiated ability to reprogram tumor and immune biology in preclinical models, suggesting that these effects are not necessarily shared by other dual PI3K/mTOR inhibitors. Kazia believes this…
News from Kazia Therapeutics Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Kazia Therapeutics Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Sep 22, 2026,…
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing... SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA)…
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Kazia Therapeutics (KZIA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), Kazia Therapeutics (KZIA) and Mirum Pharmaceuticals (MIRM) with bullish sentiments. In a report released yesterday,…
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
28 Aug, 2026, 04:01 CST Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83%…
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to... Planned Enrollment to Increase from 12 to 36 Patients Following Continued…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- theglobeandmail.com3
- prnewswire.com2
- macaubusiness.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.